# Isoquercetin in Sickle Cell Anemia

> **NCT04474626** · PHASE2 · WITHDRAWN · sponsor: **Jeffrey Zwicker, MD**

## Conditions studied

- Sickle Cell Disease
- Sickle Cell-Beta0-Thalassemia

## Interventions

- **DRUG:** Isoquercetin

## Key facts

- **NCT ID:** NCT04474626
- **Lead sponsor:** Jeffrey Zwicker, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial did not activate
- **Last updated:** 2021-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04474626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04474626, "Isoquercetin in Sickle Cell Anemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04474626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*